Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
DSGN · Why this verdict
Why Design Therapeutics (DSGN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
An elevated put/call ratio of 8.00 and high implied volatility (112%) suggest the options market is pricing meaningful downside risk or hedging activity despite the recent price strength. Risk breakdown | The put/call ratio should normalize toward 1.0 or lower as options positioning becomes less skewed toward puts. | →Stable |
| CounterA high put/call ratio at a small-cap biotech can result from thin options open interest where a handful of contracts skew the ratio, rather than broad-based bearish conviction. | ||
Momentum is very strong (score 8.1, RSI 88 overbought) with rising volume and price above the 200-day moving average, indicating a powerful recent uptrend. Momentum breakdown | Momentum should moderate to a more sustainable range while price holds its gains above the 200-day MA. | →Stable |
| CounterRSI 88 is deep into overbought territory and historically prone to sharp mean-reversion pullbacks, especially in small-cap biotech names. | ||
The company has posted a strong earnings record (3 beats out of the last 4 quarters), supporting near-term catalyst confidence. Catalyst breakdown | The beat rate should hold at 3 or more beats out of the next 4 reporting quarters. | →Stable |
| CounterLight analyst coverage, flagged as dampening the signal, means the beat comparisons are against a small set of estimates that could be easily gamed or unreliable. | ||
Despite strong momentum, the risk/reward asymmetry ratio (1.12) fails the engine's 1.5 minimum threshold, indicating the 16.8% upside does not sufficiently outweigh the 15% downside at current prices. Engine gate (failed) | The asymmetry ratio should rise above 1.5 as either upside expands or downside risk contracts. | →Stable |
| CounterAsymmetry calculations are sensitive to the specific stop-loss and take-profit methodology used, and a modest change in target methodology could flip the ratio above the gate threshold without any change in underlying fundamentals. | ||
An elevated put/call ratio of 8.00 and high implied volatility (112%) suggest the options market is pricing meaningful downside risk or hedging activity despite the recent price strength.
→StableRisk breakdown
- Expectation
- The put/call ratio should normalize toward 1.0 or lower as options positioning becomes less skewed toward puts.
CounterA high put/call ratio at a small-cap biotech can result from thin options open interest where a handful of contracts skew the ratio, rather than broad-based bearish conviction.
Momentum is very strong (score 8.1, RSI 88 overbought) with rising volume and price above the 200-day moving average, indicating a powerful recent uptrend.
→StableMomentum breakdown
- Expectation
- Momentum should moderate to a more sustainable range while price holds its gains above the 200-day MA.
CounterRSI 88 is deep into overbought territory and historically prone to sharp mean-reversion pullbacks, especially in small-cap biotech names.
The company has posted a strong earnings record (3 beats out of the last 4 quarters), supporting near-term catalyst confidence.
→StableCatalyst breakdown
- Expectation
- The beat rate should hold at 3 or more beats out of the next 4 reporting quarters.
CounterLight analyst coverage, flagged as dampening the signal, means the beat comparisons are against a small set of estimates that could be easily gamed or unreliable.
Despite strong momentum, the risk/reward asymmetry ratio (1.12) fails the engine's 1.5 minimum threshold, indicating the 16.8% upside does not sufficiently outweigh the 15% downside at current prices.
→StableEngine gate (failed)
- Expectation
- The asymmetry ratio should rise above 1.5 as either upside expands or downside risk contracts.
CounterAsymmetry calculations are sensitive to the specific stop-loss and take-profit methodology used, and a modest change in target methodology could flip the ratio above the gate threshold without any change in underlying fundamentals.
TrendMatrix Research · core thesis
Engine thesis — one sentence
DSGN is riding strong overbought momentum and a solid recent earnings-beat record, but an elevated put/call ratio and a failed asymmetry gate signal the market sees limited further risk-adjusted upside at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.5 |
- ▸Overbought (RSI 81)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 37%
Insider
7.2/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 9.4 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.5 |
| growth rank | 5.0 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 1.0 |
| 52w position | 7.7 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.1 |
| days to cover | 7.2 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.7 |
| debt equity | 9.9 |
- ▸Elevated put/call: 3.69
- ▸High IV: 164%
- ▸Above max pain $1
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 7.9 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (0)
none
Reward-to-Risk
1.30
Upside
+19.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.3<1.5@spot.
The strongest dimensions are Value at 7.5, Momentum at 7.3, and Sentiment at 7.3; the weakest are Quality at 1.6, Technical at 3.5, and Risk (lower is worse) at 3.7. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Overbought Momentum Strength
Trip ifRSI falls below 30 within the next month.
- P2Elevated Put Call Hedging
Trip ifPut/call ratio stays above 5.0 for 2 consecutive months.
- P3Strong Recent Earnings Execution
Trip ifEarnings surprise falls below 0% in both of the next 2 reporting quarters.
- P4Asymmetry Gate Failure
Trip ifAsymmetry ratio stays below 1.5 for 2 consecutive quarters.